Local removal of phagocytic synovial lining cells by clodronate-liposomes decreases cartilage destruction during collagen type II arthritis

PL EM Van Lent, A E M Holthuysen, N Van Rooijen, L B A Van De Putte, W B Van Den Berg

Abstract

Objective—To investigate whether local removal of phagocytic synovial lining cells (SLCs) from the knee joint before onset of collagen type II arthritis (CIA) has an effect on development of cartilage destruction.

Methods—Phagocytic SLCs were selectively depleted by a single injection of clodronate laden liposomes in the knee joint seven days before induction of collagen type II arthritis (CIA). Clodronate laden liposomes were given in one knee joint either alone or in combination with a short-term oral treatment of dexamethasone. Cartilage damage including proteoglycan depletion and chondrocyte death was measured in total knee joints sections stained with safranin-O or haematoxylin.

Results—Local removal of phagocytic SLCs, seven days before arthritis onset, prevented cell influx for the larger part. Chondrocyte death was significantly decreased in the SLC depleted arthritic joint both at an early (6 days) and late (12 days) time point after CIA induction. However, depletion of proteoglycans from femoral and patellar cartilage layers was not prevented. If the mild acute inflammation caused by a single clodronate laden liposome injection in the left knee joint, was blocked by a short-term (on consecutive days 9, 8, 7, 6, 5 before CIA onset) oral treatment with dexamethasone, cell influx, but also proteoglycan depletion was almost completely blocked. In the contralateral control right knee joint prominent cell influx and severe cartilage damage was observed, indicating that there was no effect of dexamethasone anymore at the onset of CIA.

Conclusions—This study shows that removal of phagocytic lining cells before CIA induction, particularly in the presence of a short-term treatment with dexamethasone, decreases cartilage destruction.

(D Ann Rheum Dis 1998;57:408–413)

Destruction of cartilage is one of the main features during rheumatoid arthritis (RA) that leads to joint disability. Cartilage destruction is probably caused by substances released by both infiltrating inflammatory cells and local activated synovial cells.1 Treatments inhibiting influx of inflammatory cells and local synovial cells might be most effective in preventing cartilage destruction during RA.

In earlier studies we found that phagocytic lining cells, forming an integral part of the lining layer covering the inside of diarthrodial joints, play a crucial part in the onset of joint inflammation.2-4 It was found that selective removal of these cells from the murine knee joint by a single local injection of clodronate laden liposomes before onset of experimental arthritis, prevented the larger part of inflammation. This was found in both models expressing mild reversible inflammation like immune complex arthritis5 as well as models that develop severe irreversible inflammation like collagen type II arthritis.7 Phagocytic lining cells probably form an important source of chemokines released after activation by pro-inflammatory cytokines like interleukin 1 (IL1) and tumour necrosis factor (TNF). Local injection of IL1 in knee joints of normal6 or immunised7 mice depleted of phagocytic lining cells failed to develop inflammation whereas substantial inflammation was observed in controls. Apart from producing pro-inflammatory agents, macrophage-like lining cells also produce enzymes like collagenases,6 stromelysins,7 cathepsins,9 and proteoglycanases.7 Although these enzymes might be directly involved in cartilage degradation they are probably more important in stimulation of pro-metalloproteinases released from fibroblast-like synoviocytes.9

To investigate whether macrophage-like lining cells are involved in cartilage destruction, we selectively depleted these cells by a single local injection of clodronate laden liposomes in the knee joint of mice before arthritis induction.10 Phagocytic lining cells selectively absorb clodronate laden liposomes and subsequently die, probably of apoptosis.11 12 As a model we used collagen type II arthritis (CIA). CIA is extensively studied to understand pathogenetic events in human arthritic joints.13 14 CIA is a highly aggressive arthritis with early loss of proteoglycans and chondrocyte death leading to complete loss of articular cartilage in the later phases of arthritis. We investigated the loss of proteoglycans from the cartilage matrix and chondrocyte death by histological examination in synovial lining cells (SLC) depleted knee joints at several time points (6 and 12 days) after onset of CIA. As disease expression of CIA starts gradually 3–4 weeks after immunisation in some mice,
Depletion of macrophages from synovial lining is commonly taken 8–10 weeks, the onset was accelerated and synchronised by giving lipopolysaccharide (LPS) systemically at day 28 after immunisation.15 16

Our results indicate that chondrocyte death but not proteoglycan loss is significantly blocked if the lining is eliminated seven days before CIA onset. Prevention of the local side effects in the knee joint caused by a single clodronate laden liposome injection with a short-term treatment of dexamethasone, almost complete block chondrocyte death and proteoglycan loss was seen whereas corticosteroid treatment on its own was without effect. This study shows that clodronate laden liposomes given locally to knee joints seem an effective tool to lower severe cartilage damage seen during CIA.

Methods
ANIMALS
Male DBA/1 lac J mice were obtained from Jackson (Bar Harbor, ME, USA). They were housed under semi-sterile conditions and fed a standard diet and tap water ad libitum. They were used between 10–12 weeks of age.

INDUCTION OF ARTHRITIS
Mice were immunised with bovine Collagen type II (100 µg) emulsified in Freund’s complete adjuvant (Difco) (Mycobacterium tuberculosis 2 mg/ml), by a subcutaneous injection in the base of the tail. The animals were boosted at day 21 with an intraperitoneal injection of 100 µg collagen type II. The onset of polyarthritis occurs around 4 to 5 weeks. The onset, incidence, and severity of arthritis is, however, highly variable within and among experiments. To synchronise the onset of arthritis in the knee joint, 40 µg of bacterial LPS15 16 was given intraperitoneally at day 28 after immunisation. Using LPS, a 100% incidence is reached expressed both in cell influx,1; minor, 2; moderate, 3; marked. Cell influx was scored on a 0–3 scale: 0; no cell influx, 1; minor, 2; moderate, 3; marked.

Depletion of the cartilage matrix was measured by determining the degree of loss of safranin-O staining intensity. Both patella and femur surfaces were screened. The scale was from 0 to 3+, where o=no depletion, 1=low, 2=moderate, and 3=severe.

Chondrocyte death was determined by measuring the ratio (%) of shrunken cells in in vitro cell death kit (data not shown).

Results
LOCAL DEPLETION OF SLC AND PROTEOGLYCAN DEGRADATION FROM CARTILAGE LAYERS DURING ACCELERATED CIA
Phagocytic SLCs were eliminated by a single injection of clodronate laden liposomes into the right knee joint. In the contralateral left knee joints control vehicles (PBS or PBS-containing liposomes) were injected. Previous studies showed that cell influx in the synovium was highly reduced for both neutrophils and macrophages.2 3 To further investigate the effect of lining depletion on proteoglycan
degradation in cartilage layers within this model, the degree of loss of red staining in the femur and patella cartilage layer was measured in Safranin-O stained total knee joint sections. Figure 1 shows that although significantly reduced cell influx was observed in the SLC depleted knee joints, proteoglycan depletion was still severe and not significantly different from controls (fig 1(A), (B)); fig 2). Comparable proteoglycan loss was measured at an early (day 6) (fig 2(A)) and late time point (day 12) after arthritis onset (fig 2(B)).

LOCAL DEPLETION OF SLC AND CHONDROCYTE DEATH
Chondrocyte death is a characteristic feature in classic and accelerated CIA. Total knee joint sections stained with haematoxylin showed shrinkage of cells and nuclei in the lacunae at day 6 after induction of arthritis.

Studying whole knee joint sections, it was found that in the first phase of control accelerated CIA (six days after onset), more chondrocyte death is observed in femur (40%) than in patellar cartilage (only 10%). In the later phase (day 12 after onset), chondrocyte death was significantly increased both in the femur (from 40 to 60%) as well as in the patella (from 10 to 50%) (fig 3(A), fig 4(A)(B)). In SLC depleted joints, chondrocyte death was significantly lower both at 6 and 12 days after CIA development. At day 6, 25% less chondrocyte death was found in the femur whereas no cell death was found in the patella cartilage. At day 12 we found a noticeable protection against chondrocyte death both in the femur (70% protection) and in the patella (60% protection) (fig 3(B)).

CLODRONATE-LIPOSOME TREATMENT COMBINED WITH DEXAMETHASONE TREATMENT
A single clodronate laden liposome injection in the knee joint of immunised mice causes synovial lining depletion but also a short-term mild inflammation, which may cause unwanted side effects on cartilage metabolism. To investigate whether the absence of a protective effect on cartilage proteoglycan loss upon full expression of CIA could be related to this early inflammation, mice were treated orally by dexamethasone on five alternate days (day 19, 20, 21, 22, and 23 after CIA induction) around the injection of clodronate-liposomes (day 21 after CIA induction). In the right knee joint, clodronate-liposomes were injected whereas in the left knee joint we injected PBS. The treatment with dexamethasone in the early phase of immunisation had no effect on the macroscopic scoring of paw swelling measured from day 28 until day 34 if compared with immunised mice, which only received the
vehicle at the same time points, excluding a systemic impact on the arthritis (fig 5). In the left PBS injected knee joint of dexamethasone treated mice, a full blown inflammation (fig 6(A), fig 7(A)) and severe cartilage destruction in femur and patella was observed (fig 6 (B), (C), fig 7(A)). However, in the contralateral lining depleted knee joint of dexamethasone treated immunised mice, cell influx was totally prevented (fig 6(A), fig 7(B)). More interestingly only minimal proteoglycan depletion was found in both patella and femur (fig 6(B), fig 7 (B)) whereas no chondrocyte death was found in the femur (fig 6(C), fig 7(C)). In SLC depleted knee joints of CIA mice that did not receive a systemic dexamethasone treatment, it was again confirmed that chondrocyte death was reduced but not proteoglycan depletion.

Figure 4  Total knee joint sections stained with haematoxylin and eosin, six days after accelerated collagen type II arthritis. Note the significantly decreased cell influx in the arthritic knee joint in which the lining was selectively removed seven days before CIA induction (B) compared with controls (A). Significantly less chondrocyte death is found particularly in the femur in lining depleted arthritic knee joints. Original magnification × 200. F=femur, P=patella, S=synovium.

Figure 5  Clinical severity of arthritis in the hindpaws of DBA/1 mice with accelerated type II collagen induced arthritis (CLA). CIA was accelerated by giving 40 µg of lipopolysaccharide (LPS) on day 28. Clodronate laden liposomes were injected in the left knee joint whereas PBS was injected in the right knee joint on day 21. One group of seven mice were treated orally with dexamethasone (1 mg/kg/day) on day 19, 20, 21, 22, 23. The control group was given the vehicle at similar time points. Clinical severity of the hind paw was scored using an arbitrary scale from 0–2 per paw. Note that the clinical severity of the hind paws was not different between dexamethasone and vehicle treated animals.

Figure 6  Cell influx, proteoglycan depletion, and chondrocyte death in knee joints of DBA/1 mice with accelerated type II collagen induced arthritis (CLA). Total knee joint sections were stained with either haematoxylin and eosin (cell influx) or safranin-o (proteoglycan loss). Cell influx and proteoglycan loss was scored on a 0–3 scale. The percentage chondrocyte death was expressed as ratio of number of empty lacunae/number of total lacunae. Clodronate laden liposomes or PBS alone was injected in the knee joint before arthritis induction. One group of seven mice was treated orally with dexamethasone (1 mg/kg/day) on days 19, 20, 21, 22, 23. Note the absence of cell infiltration and chondrocyte death and the minor proteoglycan loss in SLC depleted but not control arthritic knee joints of mice given dexamethasone. The control group was given the vehicle at similar time points. Clinical severity of the hind paws was not different between dexamethasone and vehicle treated animals (data not shown).
Discussion

In a previous study we found that local lining depletion in the knee joint blocks the larger part of the expression of the inflammatory response during CIA. In this study we show that local clodronate-liposome treatment also has beneficial effects on cartilage damage, but full protection was only found if clodronate-liposomes were applied in the presence of dexamethasone.

Severe cartilage destruction like inhibition of proteoglycan synthesis, degradation of proteoglycan, and death of chondrocytes is characteristic for collagen type II induced arthritis. Chondrocyte death, which was already prominent around day 6 after CIA onset, was significantly decreased in SLC depleted arthritic joints. Chondrocyte death observed within this model is probably caused by inflammatory mediators released by local synovial cells or infiltrating cells, or both. Persistent collagen type II immune complexes may activate infiltrating cells like PMN and macrophages. These cells are important producers of nitrogen and oxygen radicals, which may lead to either apoptosis or necrosis of chondrocytes.

As the amount of infiltrating cells is significantly reduced in SLC depleted arthritic knee joints, this may dampen the local release of radicals and thus prevent severe chondrocyte death. Activated PMN also are an important source of serine proteinases, elastase being the most prominent. Apart from its proteoglycan degrading capacity, elastase also activates proforms of metalloproteinases, like stromelysin and collagenases. Release of these enzymes by the chondrocyte may increase erosion of the cartilage matrix and chondrocyte death.

Although expression of inflammation in SLC depleted arthritic knee joints decreased significantly, there was still a considerable loss of proteoglycans that was similar to controls, suggesting that minor inflammation can still be destructive to cartilage. A recent study in the immune complex mediated arthritis showed that IL1ra treatment caused selective block of PMN influx but not monocyte influx, and this was insufficient to prevent proteoglycan degradation. Metalloproteinases and the not yet identified “aggrecanase” produced by minor amounts of infiltrating macrophages or local cells may be responsible for the observed proteoglycan loss. Release of these enzymes is strongly activated by pro-inflammatory cytokines like TNFα and IL1 and although these cytokines are lowered in lining depleted CIA joints they may still have substantial effects. Complete block of inflammatory cells by anti-adhesion (anti-CR3) antibodies in accelerated CIA knee joints prevented proteoglycan loss completely (unpublished data). This again suggests that minor inflammation may still be destructive to cartilage either directly or indirectly by activating synovial fibroblasts resulting in full blown proteoglycan depletion. In contrast with this is our previous finding in non-T cell mediated immune complex arthritis in which lining depletion before arthritis induction did not only prevent the larger part of cell influx but also around 50% of the proteoglycan depletion. This suggests that joint structures of mice that are previously immunised by complete Freund’s adjuvant like in the CIA might be more vulnerable for a small arthritic insult than joints from normal, non-immunised mice. Moreover, strain differences might also be important. Immune complex arthritis elicited in knee joints of DBA/1 mice is much more destructive to cartilage compared with arthritis raised in knee joints of C57Bl/6 mice (unpublished data). We further investigated whether we could improve the beneficial effects of clodronate-liposome treatment on cartilage damage. In earlier studies, we found that a single injection of clodronate-laden liposomes in the knee joint causes a mild, short-lasting (1–2 days) inflammation and some cartilage damage. To block only these short-lasting side effects of clodronate-laden liposomes and not the onset of arthritis, dexamethasone was given shortly before and for a few days after liposome treatment. Dexamethasone has well characterised anti-inflammatory actions. As the biological half life of dexamethasone action is between 36–72 hours, its beneficial effects wane shortly after the last injection and we found that it did not interfere with the onset of CIA five days later. Apart from the fact that the anti-inflammatory effects of dexamethasone may have subsided for the larger part at the time of onset, the use of LPS to synchronise the onset may overcome the rest inhibiting effect of dexamethasone, which leads to development of arthritis similar to the control group. Interestingly, in mice treated with dexamethasone, only minor proteoglycan loss was observed in SLC depleted knee joints whereas in the contralateral control joint, a full blown arthritis developed, showing severe proteoglycan loss. One of the dexamethasone effects is its beneficial effect on prevention of proteoglycan loss.
Depletion of macrophages from synovial lining

Proteoglycan content in the cartilage matrix is the net effect of proteoglycan degradation and proteoglycan synthesis. Dexamethasone ameliorates joint destruction by both decreasing proteoglycan degradation and inhibition of proteoglycan synthesis seen during arthritis. Apart from preventing cartilage damage, dexamethasone also efficiently downregulates inflammation. As knee joints of collagen type II immunised mice are highly vulnerable, local injection of clodronate-liposomes may apart from depleting SLCs also induce minor synovial inflammation thus priming the joint for a second arthritis insult. The short-term treatment of dexamethasone may inhibit this minor inflammation thus preventing a flare effect by the LPS treatment at day 28.

This study shows that local treatment of clodronate-liposomes in the presence of low concentrations of dexamethasone before arthritis induction ameliorates cartilage destruction during collagen type II induced arthritis. As local treatment of clodronate-liposomes decreases both expression of inflammation and cartilage damage it might be an effective treatment for joints suffering from RA.

This study was financially supported by the Maartens Clinic, Nijmegen, the Netherlands.

References:


